Advanced

Radioimmunotherapy for Prostate Cancer-Current Status and Future Possibilities.

Evans Axelsson, Susan LU ; Vilhelmsson Timmermand, Oskar LU ; Bjartell, Anders LU ; Strand, Sven-Erik LU and Elgqvist, Jörgen LU (2016) In Seminars in Nuclear Medicine 46(2). p.165-179
Abstract
Prostate cancer (PCa) is one of the most common cancers in men and is the second leading cause of cancer-related deaths in the USA. In the United States, it is the second most frequently diagnosed cancer after skin cancer, and in Europe it is number one. According to the American Cancer Society, approximately 221,000 men in the United States would be diagnosed with PCa during 2015, and approximately 28,000 would die of the disease. According to the International Agency for Research on Cancer, approximately 345,000 men were diagnosed with PCa in Europe during 2012, and despite more emphasis placed on early detection through routine screening, 72,000 men died of the disease. Hence, the need for improved therapy modalities is of utmost... (More)
Prostate cancer (PCa) is one of the most common cancers in men and is the second leading cause of cancer-related deaths in the USA. In the United States, it is the second most frequently diagnosed cancer after skin cancer, and in Europe it is number one. According to the American Cancer Society, approximately 221,000 men in the United States would be diagnosed with PCa during 2015, and approximately 28,000 would die of the disease. According to the International Agency for Research on Cancer, approximately 345,000 men were diagnosed with PCa in Europe during 2012, and despite more emphasis placed on early detection through routine screening, 72,000 men died of the disease. Hence, the need for improved therapy modalities is of utmost importance. And targeted therapies based on radiolabeled specific antibodies or peptides are a very interesting and promising alternative to increase the therapeutic efficacy and overall chance of survival of these patients. There are currently several preclinical and some clinical studies that have been conducted, or are ongoing, to investigate the therapeutic efficacy and toxicity of radioimmunotherapy (RIT) against PCa. One thing that is lacking in a lot of these published studies is the dosimetry data, which are needed to compare results between the studies and the study locations. Given the complicated tumor microenvironment and overall complexity of RIT to PCa, old and new targets and targeting strategies like combination RIT and pretargeting RIT are being improved and assessed along with various therapeutic radionuclides candidates. Given alone or in combination with other therapies, these new and improved strategies and RIT tools further enhance the clinical response to RIT drugs in PCa, making RIT for PCa an increasingly practical clinical tool. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Seminars in Nuclear Medicine
volume
46
issue
2
pages
165 - 179
publisher
Elsevier
external identifiers
  • pmid:26897720
  • scopus:84958742902
  • wos:000371190400010
ISSN
0001-2998
DOI
10.1053/j.semnuclmed.2015.10.005
language
English
LU publication?
yes
id
93a313fd-6737-45f1-b345-54c93ad47af2 (old id 8824975)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26897720?dopt=Abstract
date added to LUP
2016-03-03 15:00:48
date last changed
2017-10-22 04:21:55
@article{93a313fd-6737-45f1-b345-54c93ad47af2,
  abstract     = {Prostate cancer (PCa) is one of the most common cancers in men and is the second leading cause of cancer-related deaths in the USA. In the United States, it is the second most frequently diagnosed cancer after skin cancer, and in Europe it is number one. According to the American Cancer Society, approximately 221,000 men in the United States would be diagnosed with PCa during 2015, and approximately 28,000 would die of the disease. According to the International Agency for Research on Cancer, approximately 345,000 men were diagnosed with PCa in Europe during 2012, and despite more emphasis placed on early detection through routine screening, 72,000 men died of the disease. Hence, the need for improved therapy modalities is of utmost importance. And targeted therapies based on radiolabeled specific antibodies or peptides are a very interesting and promising alternative to increase the therapeutic efficacy and overall chance of survival of these patients. There are currently several preclinical and some clinical studies that have been conducted, or are ongoing, to investigate the therapeutic efficacy and toxicity of radioimmunotherapy (RIT) against PCa. One thing that is lacking in a lot of these published studies is the dosimetry data, which are needed to compare results between the studies and the study locations. Given the complicated tumor microenvironment and overall complexity of RIT to PCa, old and new targets and targeting strategies like combination RIT and pretargeting RIT are being improved and assessed along with various therapeutic radionuclides candidates. Given alone or in combination with other therapies, these new and improved strategies and RIT tools further enhance the clinical response to RIT drugs in PCa, making RIT for PCa an increasingly practical clinical tool.},
  author       = {Evans Axelsson, Susan and Vilhelmsson Timmermand, Oskar and Bjartell, Anders and Strand, Sven-Erik and Elgqvist, Jörgen},
  issn         = {0001-2998},
  language     = {eng},
  number       = {2},
  pages        = {165--179},
  publisher    = {Elsevier},
  series       = {Seminars in Nuclear Medicine},
  title        = {Radioimmunotherapy for Prostate Cancer-Current Status and Future Possibilities.},
  url          = {http://dx.doi.org/10.1053/j.semnuclmed.2015.10.005},
  volume       = {46},
  year         = {2016},
}